OBJECTIVES: Successful asthma management reduces the morbidity and mortality associated with the disease as well as the costs associated with treating complications.  Several treatment options exist for asthma management, many that include a steroid in combination with a long-acting beta agonist (LABA), which are referred to as “controller medications.”  The purpose of this project was to estimate the costs and effectiveness and to determine the cost-effectiveness of two combination controller medications: fluticasone propionate/salmeterol combination (SFC) and mometasone furoate/formoterol fumarate dehydrate (MF). METHODS: A Markov disease state-transition model was constructed to estimate the costs and effectiveness of SFC and MF. The analysis was conducted from a U.S. healthcare system’s perspective.  Cost data for SFC were obtained from a published study evaluating the costs of managing asthma exacerbations in the UK in primary and secondary care and cost data for MF were derived by averaging out its price from different pharmacy chains available online. All costs were converted to 2013 US dollars.  Effectiveness data and data on transition probabilities were derived from a published clinical trial. The model was run over a 12-week period using TreeAge Pro 2013. RESULTS: The cost associated with SFC treatment was estimated to be $1244 with 3 asthma controlled weeks and the cost associated with MF was $2884 with 1 asthma controlled week. The results showed that treatment with MF was dominated by SFC. CONCLUSIONS: This preliminary study shows that asthma management with SFC offers more treatment advantage and costs less compared to MF, therefore is more cost-effective than MF in asthma management.